GEN News | December 9, 2019: Rakuten Medical—which changed its name from Rakuten Aspyrian in March—raised approximately $100 million on July 31 in a Series C-1 Preferred Stock financing from Japanese ecommerce giant Rakuten, which raised its stake in Rakuten Medical to 22.6%. On November 9 at the Society for Immunotherapy of Cancer (SITC) 34th annual meeting in National Harbor, MD, the company announced new preclinical data suggesting its CD25 photoimmunotherapy treatment, plus an anti-PD1 therapy, may stimulate the immune system, and lead to a synergistic, anti-cancer activity in targeted tumors.

Read the Full Article